Paeds SAQs · haematology-oncology-and-transfusion
Long-term follow-up and late effects of childhood cancer: SAQ
Short-answer questions on the long-term follow-up and late effects of childhood cancer, covering the over eighty percent five-year survival and the chronic health condition burden, the organ-system late effects of endocrine failure with growth hormone deficiency and hypothyroidism, anthracycline cardiomyopathy, subsequent malignancy, neurocognitive decline and infertility, the treatment-summary-driven and risk-stratified lifelong surveillance built on the Children's Oncology Group guidelines, and the structured transition of the adolescent survivor to the adult late-effects service.
On this page
Study tools
Target exams
This young woman is a childhood cancer survivor at the age of twenty-two, fifteen years after the treatment of a Hodgkin lymphoma with a high cumulative anthracycline dose and a significant chest radiation exposure. Her exercise intolerance is the symptom that demands the assessment for the anthracycline cardiomyopathy, and her treatment exposures demand the comprehensive risk-stratified surveillance across the cardiac, the endocrine and the oncologic domains. The task is to recognise the late effects, to order the surveillance, and to build the transition plan. [5]
Question 1 (10 marks)
Outline your approach to the risk-stratified assessment and the surveillance for this survivor's late effects. [2]
A full-mark answer covers the treatment-summary-driven surveillance, the targeted history and examination, and the organ-system investigations mapped to the specific exposures. [1]
The treatment summary and the risk stratification (2 marks). The assessment begins with the treatment summary, which documents the diagnosis, the cumulative anthracycline dose of three hundred milligrams per square metre, the chest radiation of thirty gray, and the other exposures. The summary is mapped onto the Children's Oncology Group guidelines to generate the risk-stratified surveillance plan. The anthracycline dose places her in the high-risk group for the cardiomyopathy, because it exceeds the two hundred and fifty milligrams per square metre threshold, and the chest radiation places her in the high-risk group for the breast cancer, because it exceeds the twenty gray threshold. [2]
The targeted history and examination (2 marks). The history probes the exercise tolerance, the dyspnoea and the palpitations for the cardiomyopathy, the menstrual and the fertility history for the gonadal failure, and the cognitive and the mood status for the neurocognitive late effect. The examination measures the height and the weight, palpates the thyroid, examines the breasts, auscultates the heart for the gallop, and examines the skin. The exercise intolerance is the symptom that directs the urgent cardiac assessment. [3][5]
The cardiac investigation (3 marks). The urgent echocardiogram is the key test, because the exercise intolerance in a survivor with a cumulative anthracycline dose of three hundred milligrams per square metre may be the clinical declaration of the cardiomyopathy. The echocardiogram measures the left ventricular ejection fraction and the shortening fraction, and the electrocardiogram looks for the arrhythmia. The troponin and the natriuretic peptide are the adjuncts, and the cardiac magnetic resonance imaging is considered if the echocardiogram is discordant. The cardio-oncology team is involved early. [5]
The endocrine and the oncologic surveillance (3 marks). The endocrine panel includes the thyroid function, the hypothalamic-pituitary hormone panel, and the bone density, because the chest radiation and the chemotherapy carry the endocrine late-effect risk. The breast surveillance is the annual mammography and the breast magnetic resonance imaging, beginning at eight years after the radiation or at age twenty five, whichever occurs later, and because she is twenty-two and fifteen years post-radiation she has already entered the surveillance window. The thyroid examination and the ultrasound are performed for the thyroid cancer risk, and the neuropsychological assessment is considered for the cognitive late effect. [3][9]
References6ShowHide
- [1]Oeffinger KC, Mertens AC, Sklar CA Chronic health conditions in adult survivors of childhood cancer N Engl J Med, 2006.PMID 17035650
- [2]DeVine A, Landier W, Hudson MM The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review JAMA Oncol, 2025.PMID 39976936
- [3]Chemaitilly W, Cohen LE, Mostoufi-Moab S Endocrine Late Effects in Childhood Cancer Survivors J Clin Oncol, 2018.PMID 29874130
- [5]Leerink JM, de Baat EC, Feijen EAM Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review JACC CardioOncol, 2020.PMID 34396245
- [9]Armstrong GT, Liu W, Leisenring W Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study J Clin Oncol, 2011.PMID 21709189
- [11]Fardell JE, Wakefield CE, Signorelli C Transition of childhood cancer survivors to adult care: The survivor perspective Pediatr Blood Cancer, 2017.PMID 28436208